Hubbry Logo
logo
FOSB avatar
FOSB
Community hub

FOSB

logo
0 subscribers
Read side by side
FOSB
View on Wikipedia
from Wikipedia
For the silicon wafer box, see FOUP.

FOSB
Identifiers
AliasesFOSB, AP-1, G0S3, GOS3, GOSB, FosB, ΔFosB, FosB proto-oncogene, AP-1 transcription factor subunit
External IDsOMIM: 164772; MGI: 95575; HomoloGene: 31403; GeneCards: FOSB; OMA:FOSB - orthologs
Orthologs
SpeciesHumanMouse
Entrez

2354

14282

Ensembl

ENSG00000125740

ENSMUSG00000003545

UniProt

P53539

P13346

RefSeq (mRNA)

NM_001114171
NM_006732

NM_008036
NM_001347586

RefSeq (protein)

NP_001107643
NP_006723

NP_001334515
NP_032062

Location (UCSC)Chr 19: 45.47 – 45.48 MbChr 7: 19.04 – 19.04 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Protein fosB, also known as FosB and G0/G1 switch regulatory protein 3 (G0S3), is a protein that in humans is encoded by the FBJ murine osteosarcoma viral oncogene homolog B (FOSB) gene.[5][6][7]

The FOS gene family consists of four members: FOS, FOSB, FOSL1, and FOSL2. These genes encode leucine zipper proteins that can dimerize with proteins of the JUN family (e.g., c-Jun, JunD), thereby forming the transcription factor complex AP-1. As such, the FOS proteins have been implicated as regulators of cell proliferation, differentiation, and transformation.[5] FosB and its truncated splice variants, ΔFosB and further truncated Δ2ΔFosB, are all involved in osteosclerosis, although Δ2ΔFosB lacks a known transactivation domain, in turn preventing it from affecting transcription through the AP-1 complex.[8]

The ΔFosB splice variant has been identified as playing a central, crucial[9][10] role in the development and maintenance of addiction.[9][11][12] ΔFosB overexpression (i.e., an abnormally and excessively high level of ΔFosB expression which produces a pronounced gene-related phenotype) triggers the development of addiction-related neuroplasticity throughout the reward system and produces a behavioral phenotype that is characteristic of an addiction.[9][12][13] ΔFosB differs from the full length FosB and further truncated Δ2ΔFosB in its capacity to produce these effects, as only accumbal ΔFosB overexpression is associated with pathological responses to drugs.[14]

DeltaFosB

[edit]

DeltaFosB – more commonly written as ΔFosB – is a truncated splice variant of the FOSB gene.[15] ΔFosB has been implicated as a critical factor in the development of virtually all forms of behavioral and drug addictions.[10][11][16] In the brain's reward system, it is linked to changes in a number of other gene products, such as CREB and sirtuins.[17][18][19] In the body, ΔFosB regulates the commitment of mesenchymal precursor cells to the adipocyte or osteoblast lineage.[20]

In the nucleus accumbens, ΔFosB functions as a "sustained molecular switch" and "master control protein" in the development of an addiction.[9][21][22] In other words, once "turned on" (sufficiently overexpressed) ΔFosB triggers a series of transcription events that ultimately produce an addictive state (i.e., compulsive reward-seeking involving a particular stimulus); this state is sustained for months after cessation of drug use due to the abnormal and exceptionally long half-life of ΔFosB isoforms.[9][21][22] ΔFosB expression in D1-type nucleus accumbens medium spiny neurons directly and positively regulates drug self-administration and reward sensitization through positive reinforcement while decreasing sensitivity to aversion.[9][12] Based upon the accumulated evidence, a medical review from late 2014 argued that accumbal ΔFosB expression can be used as an addiction biomarker and that the degree of accumbal ΔFosB induction by a drug is a metric for how addictive it is relative to others.[9]

Chronic administration of anandamide, or N-arachidonylethanolamide (AEA), an endogenous cannabinoid, and additives such as sucralose, a noncaloric sweetener used in many food products of daily intake, are found to induce an overexpression of ΔFosB in the infralimbic cortex (Cx), nucleus accumbens (NAc) core, shell, and central nucleus of amygdala (Amy), that induce long-term changes in the reward system.[23]

Role in addiction

[edit]
Addiction and dependence glossary[12][24][25]
  • addiction – a neuropsychological disorder characterized by a persistent and intense urge to use a drug or engage in a behavior that produces natural reward
  • addictive drug – psychoactive substances that with repeated use are associated with significantly higher rates of substance use disorders, due in large part to the drug's effect on brain reward systems
  • dependence – an adaptive state associated with a withdrawal syndrome upon cessation of repeated exposure to a stimulus (e.g., drug intake)
  • drug sensitization or reverse tolerance – the escalating effect of a drug resulting from repeated administration at a given dose
  • drug withdrawal – symptoms that occur upon cessation of repeated drug use
  • physical dependence – dependence that involves persistent physical–somatic withdrawal symptoms (e.g., delirium tremens and nausea)
  • psychological dependence – dependence that is characterised by emotional-motivational withdrawal symptoms (e.g., anhedonia and anxiety) that affect cognitive functioning.
  • reinforcing stimuli – stimuli that increase the probability of repeating behaviors paired with them
  • rewarding stimuli – stimuli that the brain interprets as intrinsically positive and desirable or as something to approach
  • sensitization – an amplified response to a stimulus resulting from repeated exposure to it
  • substance use disorder – a condition in which the use of substances leads to clinically and functionally significant impairment or distress
  • drug tolerance – the diminishing effect of a drug resulting from repeated administration at a given dose


Signaling cascade in the nucleus accumbens that results in psychostimulant addiction
The signaling cascade involved in psychostimulant addiction
The image above contains clickable links
This diagram depicts the signaling events in the brain's reward center that are induced by chronic high-dose exposure to psychostimulants that increase the concentration of synaptic dopamine, like amphetamine, methamphetamine, and phenethylamine. Following presynaptic dopamine and glutamate co-release by such psychostimulants,[26][27] postsynaptic receptors for these neurotransmitters trigger internal signaling events through a cAMP-dependent pathway and a calcium-dependent pathway that ultimately result in increased CREB phosphorylation.[26][28][29] Phosphorylated CREB increases levels of ΔFosB, which in turn represses the c-Fos gene with the help of corepressors;[26][21][30] c-Fos repression acts as a molecular switch that enables the accumulation of ΔFosB in the neuron.[31] A highly stable (phosphorylated) form of ΔFosB, one that persists in neurons for 1–2 months, slowly accumulates following repeated high-dose exposure to stimulants through this process.[21][30] ΔFosB functions as "one of the master control proteins" that produces addiction-related structural changes in the brain, and upon sufficient accumulation, with the help of its downstream targets (e.g., nuclear factor kappa B), it induces an addictive state.[21][30]

Chronic addictive drug use causes alterations in gene expression in the mesocorticolimbic projection, which arise through transcriptional and epigenetic mechanisms.[10][32][33] The most important transcription factors that produce these alterations are ΔFosB, cyclic adenosine monophosphate (cAMP) response element binding protein (CREB), and nuclear factor kappa B (NF-κB).[10] ΔFosB is the most significant biomolecular mechanism in addiction because the overexpression of ΔFosB in the D1-type medium spiny neurons in the nucleus accumbens is necessary and sufficient for many of the neural adaptations and behavioral effects (e.g., expression-dependent increases in drug self-administration and reward sensitization) seen in drug addiction.[9][10][12] ΔFosB overexpression has been implicated in addictions to alcohol, cannabinoids, cocaine, methylphenidate, nicotine, opioids, phencyclidine, propofol, and substituted amphetamines, among others.[9][10][32][34][35] ΔJunD, a transcription factor, and G9a, a histone methyltransferase, both oppose the function of ΔFosB and inhibit increases in its expression.[10][12][36] Increases in nucleus accumbens ΔJunD expression (via viral vector-mediated gene transfer) or G9a expression (via pharmacological means) reduces, or with a large increase can even block, many of the neural and behavioral alterations seen in chronic drug abuse (i.e., the alterations mediated by ΔFosB).[13][10] Repression of c-Fos by ΔFosB, which consequently further induces expression of ΔFosB, forms a positive feedback loop that serves to indefinitely perpetuate the addictive state.

ΔFosB also plays an important role in regulating behavioral responses to natural rewards, such as palatable food, sex, and exercise.[10][16] Natural rewards, similar to drugs of abuse, induce gene expression of ΔFosB in the nucleus accumbens, and chronic acquisition of these rewards can result in a similar pathological addictive state through ΔFosB overexpression.[10][11][16] Consequently, ΔFosB is the key mechanism involved in addictions to natural rewards (i.e., behavioral addictions) as well;[10][11][16] in particular, ΔFosB in the nucleus accumbens is critical for the reinforcing effects of sexual reward.[16] Research on the interaction between natural and drug rewards suggests that dopaminergic psychostimulants (e.g., amphetamine) and sexual behavior act on similar biomolecular mechanisms to induce ΔFosB in the nucleus accumbens and possess bidirectional reward cross-sensitization effects[note 1] that are mediated through ΔFosB.[11][37] This phenomenon is notable since, in humans, a dopamine dysregulation syndrome, characterized by drug-induced compulsive engagement in natural rewards (specifically, sexual activity, shopping, and gambling), has also been observed in some individuals taking dopaminergic medications.[11]

ΔFosB inhibitors (drugs or treatments that oppose its action or reduce its expression) may be an effective treatment for addiction and addictive disorders.[38] Current medical reviews of research involving lab animals have identified a drug class – class I histone deacetylase inhibitors[note 2] – that indirectly inhibits the function and further increases in the expression of accumbal ΔFosB by inducing G9a expression in the nucleus accumbens after prolonged use.[13][36][39][40] These reviews and subsequent preliminary evidence which used oral administration or intraperitoneal administration of the sodium salt of butyric acid or other class I HDAC inhibitors for an extended period indicate that these drugs have efficacy in reducing addictive behavior in lab animals[note 3] that have developed addictions to ethanol, psychostimulants (i.e., amphetamine and cocaine), nicotine, and opiates;[36][40][41][42] however, as of August 2015, few clinical trials involving humans with addiction and any HDAC class I inhibitors have been conducted to test for treatment efficacy in humans or identify an optimal dosing regimen.[note 4]

Plasticity in cocaine addiction

[edit]
See also: Epigenetics of cocaine addiction
ΔFosB accumulation from excessive drug use
ΔFosB accumulation graph
Top: this depicts the initial effects of high dose exposure to an addictive drug on gene expression in the nucleus accumbens for various Fos family proteins (i.e., c-Fos, FosB, ΔFosB, Fra1, and Fra2).
Bottom: this illustrates the progressive increase in ΔFosB expression in the nucleus accumbens following repeated twice daily drug binges, where these phosphorylated (35–37 kilodalton) ΔFosB isoforms persist in the D1-type medium spiny neurons of the nucleus accumbens for up to 2 months.[22][30]

ΔFosB levels have been found to increase upon the use of cocaine.[44] Each subsequent dose of cocaine continues to increase ΔFosB levels with no apparent ceiling of tolerance.[citation needed] Elevated levels of ΔFosB leads to increases in brain-derived neurotrophic factor (BDNF) levels, which in turn increases the number of dendritic branches and spines present on neurons involved with the nucleus accumbens and prefrontal cortex areas of the brain. This change can be identified rather quickly, and may be sustained weeks after the last dose of the drug.

Transgenic mice exhibiting inducible expression of ΔFosB primarily in the nucleus accumbens and dorsal striatum exhibit sensitized behavioural responses to cocaine.[45] They self-administer cocaine at lower doses than control,[46] but have a greater likelihood of relapse when the drug is withheld.[22][46] ΔFosB increases the expression of AMPA receptor subunit GluR2[45] and also decreases expression of dynorphin, thereby enhancing sensitivity to reward.[22]

Neural and behavioral effects of validated ΔFosB transcriptional targets[9][17]
Target
gene 		Target
expression 		Neural effects Behavioral effects
c-Fos ↓ Molecular switch enabling the chronic
induction of ΔFosB[note 5]		 –
dynorphin ↓
[note 6]		  • Downregulation of κ-opioid feedback loop  • Diminished self-extinguishing response to drug
NF-κB ↑  • Expansion of Nacc dendritic processes
 • NF-κB inflammatory response in the NAcc
 • NF-κB inflammatory response in the CPTooltip caudate putamen
  • Increased drug reward
 • Locomotor sensitization
GluR2 ↑  • Decreased sensitivity to glutamate  • Increased drug reward
Cdk5 ↑  • GluR1 synaptic protein phosphorylation
 • Expansion of NAcc dendritic processes		  • Decreased drug reward
(net effect)
[edit]
Form of neuroplasticity
or behavioral plasticity 		Type of reinforcer Ref.
Opiates Psychostimulants High fat or sugar food Sexual intercourse Physical exercise
(aerobic) 		Environmental
enrichment
ΔFosB expression in
nucleus accumbens D1-type MSNsTooltip medium spiny neurons 		↑ ↑ ↑ ↑ ↑ ↑ [11]
Behavioral plasticity
Escalation of intake Yes Yes Yes [11]
Psychostimulant
cross-sensitization 		Yes Not applicable Yes Yes Attenuated Attenuated [11]
Psychostimulant
self-administration 		↑ ↑ ↓ ↓ ↓ [11]
Psychostimulant
conditioned place preference 		↑ ↑ ↓ ↑ ↓ ↑ [11]
Reinstatement of drug-seeking behavior ↑ ↑ ↓ ↓ [11]
Neurochemical plasticity
CREBTooltip cAMP response element-binding protein phosphorylation
in the nucleus accumbens 		↓ ↓ ↓ ↓ ↓ [11]
Sensitized dopamine response
in the nucleus accumbens 		No Yes No Yes [11]
Altered striatal dopamine signaling ↓DRD2, ↑DRD3 ↑DRD1, ↓DRD2, ↑DRD3 ↑DRD1, ↓DRD2, ↑DRD3 ↑DRD2 ↑DRD2 [11]
Altered striatal opioid signaling No change or
↑μ-opioid receptors		 ↑μ-opioid receptors
↑κ-opioid receptors		 ↑μ-opioid receptors ↑μ-opioid receptors No change No change [11]
Changes in striatal opioid peptides ↑dynorphin
No change: enkephalin		 ↑dynorphin ↓enkephalin ↑dynorphin ↑dynorphin [11]
Mesocorticolimbic synaptic plasticity
Number of dendrites in the nucleus accumbens ↓ ↑ ↑ [11]
Dendritic spine density in
the nucleus accumbens 		↓ ↑ ↑ [11]

Other functions in the brain

[edit]

Viral overexpression of ΔFosB in the output neurons of the nigrostriatal dopamine pathway (i.e., the medium spiny neurons in the dorsal striatum) induces levodopa-induced dyskinesias in animal models of Parkinson's disease.[47][48] Dorsal striatal ΔFosB is overexpressed in rodents and primates with dyskinesias;[48] postmortem studies of individuals with Parkinson's disease that were treated with levodopa have also observed similar dorsal striatal ΔFosB overexpression.[48] Levetiracetam, an antiepileptic drug, has been shown to dose-dependently decrease the induction of dorsal striatal ΔFosB expression in rats when co-administered with levodopa;[48] the signal transduction involved in this effect is unknown.[48]

ΔFosB expression in the nucleus accumbens shell increases resilience to stress and is induced in this region by acute exposure to social defeat stress.[49][50][51]

Antipsychotic drugs have been shown to increase ΔFosB as well, more specifically in the prefrontal cortex. This increase has been found to be part of pathways for the negative side effects that such drugs produce.[52]

See also

[edit]

Notes

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

FOSB

View on Grokipedia
from Grokipedia
FosB proto-oncogene, AP-1 transcription factor subunit (FOSB) is a human gene that encodes a leucine zipper protein belonging to the Fos subfamily of transcription factors, which dimerizes with proteins from the Jun family to form the AP-1 complex and regulate gene expression by binding to TPA-responsive elements (TREs) in DNA.[1] The FOSB protein is involved in modulating cellular responses to diverse stimuli, including growth factors, hormones, mechanical stress, and xenobiotics, thereby influencing processes such as cell proliferation, differentiation, and transformation.[1] Alternative splicing of the FOSB gene produces multiple isoforms, most notably the full-length FosB (approximately 46–50 kDa) and the truncated ΔFosB (35–37 kDa), which lacks a portion of the C-terminal domain and exhibits greater stability with a prolonged half-life compared to the transient full-length form.[1][2] In the context of neuroscience, ΔFosB accumulates in brain regions such as the nucleus accumbens and dorsal striatum following repeated exposure to drugs of abuse like cocaine and morphine, functioning as a sustained molecular switch that drives long-term neural plasticity, heightened drug sensitivity, and vulnerability to relapse by altering gene expression and synaptic morphology.[2] This isoform heterodimerizes primarily with JunD to form stable AP-1 complexes that induce or repress target genes, including those involved in glutamate receptor subunits (e.g., GluR2) and cyclin-dependent kinase 5 (Cdk5), contributing to compulsive behaviors and reward pathways.[2] Beyond addiction, FOSB gene products play essential roles in electrophysiological and behavioral adaptations to stimuli like motor seizures, as well as in hippocampal neurogenesis, learning, memory, and nurturing behaviors toward offspring.[3][4] As a proto-oncogene, FOSB has been implicated in tumorigenesis due to its capacity to encode a nuclear transcriptional activator homologous to c-Fos in functionally critical domains, potentially promoting cellular transformation when dysregulated.[5] Overall, the FOSB protein's involvement in AP-1-mediated transcription underscores its broad significance in both normal physiological regulation and pathological conditions, including neurological disorders and cancer.[6]

Gene and Protein Basics

Genomic Organization

The FOSB gene is located on the long arm of human chromosome 19 at the q13.32 cytogenetic band, spanning genomic positions 45,467,996 to 45,475,179 (GRCh38.p14 assembly), which corresponds to approximately 7.2 kb.[1] In mice, the orthologous Fosb gene resides on chromosome 7 at positions 19,036,621 to 19,043,970 (GRCm39 assembly), approximately 19.04 Mb from the pter end, reflecting high sequence conservation across mammals.[7] This positioning aligns FOSB with other members of the FOS family (FOS, FOSL1, FOSL2), which share structural and functional similarities as leucine zipper transcription factors.[1] The gene consists of four exons interrupted by three introns, with intron-exon boundaries conserved relative to the FOS gene, spanning a total genomic length of about 7 kb.[8] The promoter region, located upstream of the transcription start site near a TATA box, includes key regulatory motifs such as a serum response element (SRE) and an AP-1 binding site, enabling rapid transcriptional activation in response to extracellular stimuli like growth factors (via SRE-mediated signaling) and stress signals.[9] These elements facilitate FOSB's role as an immediate-early gene, with induction observed under conditions such as serum stimulation or acute restraint stress. Evolutionarily, FOSB belongs to the conserved FOS family of proto-oncogenes, originally identified through its homology to the viral oncogene v-fos in the FBJ murine osteosarcoma virus, which integrates cellular sequences to promote tumorigenesis.[1] The family's leucine zipper domain and basic DNA-binding regions exhibit strong sequence conservation from rodents to humans, underscoring their fundamental roles in cellular responses across vertebrates.[1] Additional regulatory elements include distal enhancers that modulate tissue-specific expression and microRNA binding sites in the 3' untranslated region; for instance, miR-27a-3p directly targets FOSB mRNA to suppress its expression in contexts like inflammatory or proliferative responses in immunoglobulin A nephropathy.[10]

Protein Characteristics

FOSB encodes a protein of 338 amino acids with a calculated molecular mass of approximately 36 kDa (apparent ~45–50 kDa on SDS-PAGE due to post-translational modifications). The protein contains a characteristic basic leucine zipper (bZIP) domain at its C-terminus, which facilitates both sequence-specific DNA binding and dimerization with partner proteins. This domain is essential for the protein's function as a component of the AP-1 transcription factor complex.[4][11] FOSB primarily functions through heterodimerization with members of the JUN family (such as c-JUN, JUNB, and JUND) to form the dimeric AP-1 transcription factor. These heterodimers bind to the TPA-responsive element (TRE), a palindromic DNA consensus sequence 5'-TGACTCA-3' found in the regulatory regions of numerous target genes involved in cellular responses to stimuli. Unlike some other FOS family members, FOSB exhibits relatively lower transactivation potential but contributes to the diversity of AP-1 binding specificities.[12][13] The activity and stability of FOSB are regulated by post-translational modifications, notably phosphorylation within the N-terminal region by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway. Such phosphorylation events enhance transcriptional activity and influence protein turnover. Full-length FOSB possesses a short half-life of approximately 2 hours, mediated by ubiquitin-dependent proteasomal degradation targeting specific C-terminal degron domains, which ensures transient expression in response to cellular signals.[14][15] As an immediate-early gene product, FOSB expression is rapidly and transiently upregulated by diverse extracellular stimuli, including neurotransmitters such as glutamate, cytokines like interleukin-1, and environmental stressors such as UV light, without requiring de novo protein synthesis. This induction pattern positions FOSB as a key mediator in linking external signals to genomic responses.[16][17]

Isoforms and Expression

Full-Length FosB

Full-length FosB, the canonical isoform of the FosB protein encoded by the fosB gene, is a 338-amino-acid transcription factor belonging to the AP-1 family, characterized by its N-terminal regulatory domain, central basic leucine zipper (bZIP) domain for DNA binding and dimerization with Jun proteins, and a complete C-terminal transactivation domain (TAD) spanning approximately 101 amino acids.[18] This full TAD distinguishes it from more stable truncated variants like ΔFosB, which lacks this region and exhibits attenuated transcriptional activation, allowing full-length FosB to potently drive gene expression upon forming AP-1 heterodimers that bind TPA-responsive elements (TREs) in target promoters.[19] The bZIP domain facilitates specific interactions with DNA and Jun partners, enabling robust activator function in response to cellular signals.[20] As an immediate early gene (IEG) product, full-length FosB expression is transiently induced within minutes to hours following acute stimuli, peaking rapidly before returning to basal levels, a pattern that contrasts with the prolonged accumulation of stable variants under chronic conditions.[21] In fibroblasts, serum growth factors such as platelet-derived growth factor trigger fosB transcription, promoting entry into the G1 phase of the cell cycle.[20] Similarly, in osteoblasts, mechanical stressors like cyclic strain or fluid shear induce FosB expression, initiating osteogenic gene programs.[22] In neurons, acute challenges including seizures rapidly upregulate FosB in cortical and hippocampal regions, supporting immediate adaptive responses without long-term persistence.[23] The instability of full-length FosB, with a half-life of 1-2 hours, arises from C-terminal degron domains that target the protein for ubiquitin-dependent proteasomal degradation, thereby restricting its activity to short durations and preventing prolonged signaling that could disrupt cellular homeostasis, unlike the degradation-resistant truncated forms.[24][25] In non-neural tissues, full-length FosB drives cell cycle progression by activating cyclin D1 expression in fibroblasts, facilitating G0/G1 transition and proliferation in response to mitogenic cues.[26] It also contributes to lineage commitment, such as in adipocyte differentiation, where early induction of FosB alongside other AP-1 components upregulates genes like aP2 to promote preadipocyte maturation into lipid-accumulating cells.[27] These functions underscore its role in transient, stimulus-driven regulation of growth and specialization in peripheral tissues.[28]

ΔFosB Variant

The ΔFosB variant is primarily generated through alternative splicing of the fosB pre-mRNA, which involves the removal of an exonic intron within exon 4, resulting in a C-terminally truncated protein that lacks the final 101 amino acids of full-length FosB, including the transactivation domain (TAD) and associated degron sequences.[29] This truncation produces a protein of approximately 33-37 kDa, depending on post-translational modifications, and renders ΔFosB incapable of robust transcriptional activation on its own but capable of forming AP-1 complexes via its retained basic leucine zipper (bZIP) domain.[30] Although proteolysis has been implicated in some regulatory contexts for Fos family proteins, the primary mechanism for ΔFosB formation is this splicing event, which evades rapid turnover by eliminating ubiquitin-proteasome targeting signals present in the full-length isoform.[15] A further processed form, Δ2ΔFosB, arises from the ΔFosB transcript via alternative translation initiation at an internal methionine codon, producing an additional N-terminal truncation that removes approximately the first 78 amino acids and results in a protein of 28-29 kDa.[31] This variant exhibits even greater stability than ΔFosB, as it lacks additional regulatory motifs, and functions primarily as a dominant-negative regulator within AP-1 dimers, further modulating gene expression in response to sustained stimuli.[32] The hallmark of ΔFosB is its exceptional stability, stemming from the absence of C-terminal degrons that target full-length FosB for proteasomal degradation; in vivo half-lives vary by isoform and context, with the 37 kDa form persisting for up to 8-9 days (approximately 208 hours) in brain tissue, compared to hours for transient immediate-early genes.[30] This prolonged half-life—extending to weeks under chronic conditions—enables progressive accumulation with repeated exposures, as the protein is not efficiently cleared between stimuli.[33] Expression of ΔFosB is predominantly observed in neuronal populations of reward-related brain regions, such as the nucleus accumbens and dorsal striatum, where it is inducibly upregulated by chronic stressors or psychostimulant drugs rather than acute events.[30] This region-specific induction reflects its role as a molecular integrator of prolonged signaling, with accumulation driven by stability rather than increased transcription rates.[34]

Core Biological Functions

Transcriptional Regulation

FosB functions as a transcription factor within the activator protein-1 (AP-1) complex, where it heterodimerizes with Jun family proteins to bind TPA-responsive elements (TREs) in the promoters of target genes, thereby modulating gene expression in response to cellular stimuli.[35] The composition of these dimers determines the transcriptional outcome, with FosB-c-Jun heterodimers typically promoting activation of genes involved in proliferation.[36] For instance, FosB-c-Jun binding at TRE sites upregulates proliferation-related genes such as cyclin D1, facilitating cell cycle progression in various cellular contexts.[36] FosB also contributes to regulation of matrix metalloproteinase (MMP) genes through AP-1 binding, enabling extracellular matrix remodeling during cellular responses to growth factors.[37] This regulation integrates with upstream signaling pathways, including the mitogen-activated protein kinase (MAPK) cascade, which phosphorylates FosB and enhances its transcriptional activity.[38] Crosstalk with nuclear factor-κB (NF-κB) signaling further fine-tunes FosB-mediated transcription, where NF-κB can indirectly boost AP-1 activity by promoting fosB expression via serum response elements.[38] The transcriptional effects of FosB exhibit dose-dependence, influenced by the relative abundance of dimer partners; higher ratios of FosB to c-Jun amplify activation of target genes like cyclin D1.[35] Isoform differences, such as the truncated ΔFosB variant, alter activation potency compared to full-length FosB, primarily due to its enhanced stability in forming persistent AP-1 complexes.[39]

Cellular Differentiation and Proliferation

FosB plays a pivotal role in lineage commitment within mesenchymal stem cells (MSCs), directing differentiation toward osteoblasts rather than adipocytes. As part of the AP-1 transcription factor complex, FosB, in conjunction with JunD, contributes to activating Runx2 expression, a master regulator of osteoblastogenesis, via AP-1 sites in the Runx2 promoter.[40] This activation promotes the osteogenic fate in MSCs, suppressing adipogenic pathways and contributing to a shift in cell fate decisions that favor bone formation over fat accumulation. Studies using transgenic models overexpressing ΔFosB, a stable isoform of FosB, demonstrate increased osteoblast numbers and trabecular bone volume, alongside reduced adipocyte differentiation, confirming the cell-autonomous promotion of osteoblast lineage commitment.[41] In terms of proliferation control, FosB facilitates the G1/S phase transition in fibroblasts by transcriptionally activating cyclin D1 expression, which associates with CDK4 to drive cell cycle progression. Fos family members, including FosB, induce cyclin D1 mRNA and protein levels in response to growth stimuli, enabling progression through the cell cycle and supporting cellular expansion. This mechanism is evident in fosB-/- c-fos-/- double-knockout fibroblasts, which exhibit defective cyclin D1 induction and impaired entry into S phase following serum stimulation, an effect rescued by re-expression of FosB or cyclin D1.[36] In osteosclerosis models, such as those involving ΔFosB overexpression, this proliferative drive contributes to enhanced osteoblast activity and bone mass accrual.[41] FosB exhibits tissue-specific expression and regulation in bone and fat cells, where it influences signaling cascades critical for differentiation. In MSCs, which serve as precursors for both osteoblasts and adipocytes, FosB is prominently expressed in osteogenic lineages and is induced via the protein kinase A (PKA) pathway activated by cAMP. This PKA-mediated induction of FosB triggers the sustained secretion of signaling molecules such as interleukin-11 (IL-11) and insulin-like growth factor 1 (IGF-1), which further support osteogenic commitment and modulate the extracellular environment to favor bone over fat cell development.[42] Experimental evidence underscores FosB's necessity in these processes through genetic models. Transgenic mice overexpressing ΔFosB under osteoblast-specific promoters display osteosclerosis characterized by doubled osteoblast numbers and increased bone formation, independent of adipocyte effects, highlighting FosB's role in promoting differentiation and proliferation.[41] In vitro studies with human MSCs subjected to cyclic strain further confirm that FosB upregulation correlates with enhanced expression of osteoblast markers like Runx2 and collagen type I, initiating osteogenic differentiation.[22] While fosB-/- mice exhibit normal gross bone development, combined fosB-/- c-fos-/- models reveal impaired proliferative responses in mesenchymal-derived cells, emphasizing FosB's contributory function in fine-tuned differentiation under stimulatory conditions.[36]

Neural and Behavioral Roles

Synaptic Plasticity

FosB, particularly its stable isoform ΔFosB, is upregulated in response to neuronal activity associated with long-term potentiation (LTP) and long-term depression (LTD) in regions such as the hippocampus and striatum. This induction occurs through NMDA receptor-dependent signaling pathways, where synaptic activation leads to calcium influx and subsequent activation of transcription factors that promote ΔFosB expression.[43] In the hippocampus, spatial learning tasks and exposure to novel environments trigger ΔFosB accumulation in CA1 pyramidal neurons and dentate gyrus granule cells, facilitating activity-dependent gene transcription essential for synaptic strengthening.[44] Similarly, in the striatum, chronic stimuli induce ΔFosB selectively in medium spiny neurons, supporting plasticity without requiring repeated drug exposure. ΔFosB contributes to structural synaptic changes by regulating dendritic spine density and morphology, primarily through downstream targets that influence cytoskeletal dynamics and neurotrophic signaling. In hippocampal CA1 neurons, overexpression of ΔFosB increases the proportion of immature thin and stubby spines while reducing mature mushroom spines, altering the balance of synaptic connectivity critical for learning.[44] This effect is mediated in part by ΔFosB's transcriptional regulation of genes like Arc, which controls actin remodeling, and BDNF, which promotes spine maturation via TrkB receptor activation; disruptions in these targets impair spine stability in medium spiny neurons of the striatum.[45] The stability of ΔFosB, conferred by its truncated structure lacking a degradation signal, allows sustained influence on these structural adaptations over extended periods. Electrophysiological consequences of ΔFosB include modulation of AMPA receptor trafficking and neuronal intrinsic excitability, as evidenced in genetic models. In fosB knockout mice, loss of ΔFosB leads to enhanced intrinsic excitability in hippocampal CA1 pyramidal neurons, with increased action potential firing rates and reduced accommodation, indicating a tonic suppressive role in excitability homeostasis.[46] ΔFosB promotes insertion of GluR2-containing AMPA receptors at synapses, enhancing AMPA-mediated currents and supporting LTP maintenance; conditional deletion in ventral hippocampal projections disrupts this trafficking, weakening excitatory transmission. These changes underscore ΔFosB's role in fine-tuning synaptic efficacy without altering baseline NMDA currents. FOSB gene products, including ΔFosB, play a critical role in adult hippocampal neurogenesis, particularly in the subgranular zone (SGZ) of the dentate gyrus, where FosB expression is necessary for progenitor cell proliferation and differentiation into mature granule cells. Disruption of FosB in SGZ neurons impairs neurogenesis and associated memory formation, highlighting its integration with synaptic plasticity for cognitive functions.[47] Additionally, FOSB is essential for molecular, electrophysiological, and behavioral adaptations to motor seizures. In response to electroconvulsive seizures, FosB induction in the hippocampus and other regions facilitates protective plasticity, such as altered neuronal firing patterns and reduced seizure susceptibility in subsequent exposures; fosB knockout mice exhibit exacerbated behavioral responses to seizures.[3]

Reward and Motivation Pathways

FosB, particularly its stable isoform ΔFosB, exhibits high expression in key components of the brain's reward circuitry, including the nucleus accumbens (NAc), ventral tegmental area (VTA), and hypothalamus.[48] These regions form the core of mesolimbic dopamine pathways that process motivational signals.[49] Within the NAc, ΔFosB localizes predominantly to medium spiny neurons, where it modulates gene expression in response to rewarding stimuli.[50] In natural reward processing, repeated exposure to stimuli such as sexual activity, wheel running, or consumption of palatable food leads to ΔFosB accumulation in the NAc, enhancing the motivational salience of these behaviors.[51] For instance, voluntary wheel running elevates ΔFosB levels in reward pathways, promoting sustained engagement in the activity.[52] Similarly, overexpression of ΔFosB in the NAc increases sucrose preference and aspects of sexual behavior, indicating its role in amplifying natural reward sensitivity.[53] FOSB gene products also contribute to nurturing behaviors toward offspring, such as maternal care. Female fosB knockout mice display profound deficits in nurturing, including failure to retrieve pups and build nests, despite normal sensory and cognitive functions; this suggests FOSB's necessity in medial preoptic area circuits for motivated parental behaviors.[54] ΔFosB influences the balance between D1- and D2-type medium spiny neurons in the NAc, thereby shaping goal-directed behaviors. Expression in D1 medium spiny neurons enhances synaptic potentiation and promotes reward-seeking actions, while in D2 neurons, it dampens inhibitory outputs, further facilitating motivational drive.[55] This differential modulation contributes to adaptive behavioral responses in reward contexts. Regarding stress interactions, ΔFosB in hippocampal-prefrontal circuits promotes resilience to chronic stress, as demonstrated in models where circuit-specific overexpression prevents social avoidance behaviors.[56] In ventral hippocampal projections, ΔFosB drives activity changes that buffer against stress-induced deficits in prefrontal function.[56]

Role in Addiction

Molecular Switch Mechanism

The ΔFosB isoform functions as a molecular switch in addiction through its gradual accumulation in response to repeated stimuli, driven by its exceptionally long half-life of approximately 8 days, in stark contrast to the transient induction of c-Fos, which degrades within hours.[2] This stability arises from the absence of degron domains in ΔFosB and resistance to proteasomal degradation, allowing it to build up progressively in key brain regions like the nucleus accumbens over multiple exposures.[57] As a result, ΔFosB sustains transcriptional activity long after the initial stimulus ceases, converting acute responses into persistent neuroadaptations that underpin addiction vulnerability.[2] ΔFosB exerts transcriptional persistence by forming stable AP-1 transcription factor complexes, primarily with JunD, which alter chromatin structure through interactions with histone deacetylases (HDACs). For instance, ΔFosB recruits HDAC1 to deacetylate histones at specific promoters, such as that of c-fos, thereby repressing transient gene expression and reinforcing its own dominance.[58] Conversely, for activation, it engages histone acetyltransferases (HATs) and chromatin remodeling complexes like SWI/SNF to upregulate target genes, including Cdk5 in the nucleus accumbens, which modulates dendritic spine density and dopaminergic signaling via DARPP-32 phosphorylation.[57] These epigenetic modifications ensure lasting changes in gene expression programs, maintaining an addicted state independently of ongoing stimuli.[57] Experimental models demonstrate ΔFosB's causal role in addiction-like behaviors: viral-mediated overexpression in the nucleus accumbens of rodents enhances reward sensitivity and motivational drive, recapitulating key addiction phenotypes such as increased self-administration.[59] Conversely, genetic knockout of the fosB gene, which eliminates both full-length FosB and ΔFosB, impairs the development of behavioral sensitization and reduces vulnerability to addiction-related adaptations.[2] Recent studies reveal cell-type and gender specificity in ΔFosB's actions, with chronic exposure inducing broad binding changes at enhancers in both D1- and D2-type medium spiny neurons of the nucleus accumbens, though with notable differences in binding profiles between these neuronal subtypes.[60] In a 2023 analysis using CUT&RUN chromatin profiling, approximately 75% of cocaine-induced ΔFosB binding sites were shared between D1 and D2 neurons in male and female mice, yet in silico predictions indicated sex-specific regulation of genes linked to seeking behaviors, highlighting differential impacts across genders and cell types.[60] As of October 2025, a preprint reported the development of a pharmacological probe to inhibit ΔFosB in vivo, potentially offering a new therapeutic avenue for addiction.[61]

Drug-Specific Effects

ΔFosB plays a pivotal role in mediating the neuroplastic changes induced by cocaine in the nucleus accumbens (NAc), particularly through its actions on medium spiny neurons (MSNs) expressing D1 dopamine receptors. Overexpression of ΔFosB in D1-type MSNs leads to an increase in the density of immature dendritic spines, such as stubby and thin types, which enhances structural plasticity and synaptic connectivity in these neurons.[62] This spine remodeling is selective to D1 MSNs and contributes to heightened behavioral responses to cocaine, including enhanced locomotor sensitization at both low (3.75 mg/kg) and high (7.5 mg/kg) doses, as well as an amplified initial locomotor response to lower doses.[62] In the context of opioids and amphetamines, ΔFosB exerts its reinforcing effects by repressing the expression of dynorphin, an endogenous opioid peptide in NAc MSNs that normally acts via κ-opioid receptors to inhibit dopaminergic signaling and dampen reward.[63] This suppression of dynorphin removes a negative feedback mechanism on dopamine release in the ventral tegmental area, thereby potentiating the rewarding properties of these drugs and contributing to addiction vulnerability.[63] Concurrently, ΔFosB upregulates the AMPA receptor subunit GluR2 in the NAc, which alters glutamate signaling by reducing calcium permeability and AMPA currents, further facilitating synaptic adaptations that sustain reinforcement from chronic opioid or amphetamine exposure.[63] ΔFosB induction occurs in response to both natural rewards, such as sexual activity and sucrose consumption, and drug rewards, highlighting shared neural plasticity mechanisms in the NAc; however, drugs of abuse elicit a severalfold greater accumulation of ΔFosB compared to the 40–60% increases seen with natural rewards, promoting maladaptive and persistent behavioral sensitization.[64] For instance, chronic sexual experience or sucrose intake elevates ΔFosB levels, enhancing motivation for these behaviors and demonstrating cross-sensitization, yet the exaggerated ΔFosB buildup from drugs like cocaine or amphetamines drives pathological overconsumption and loss of control.[64] Persistent elevation of ΔFosB in the NAc following drug abstinence, due to its long half-life of approximately 8 days, sustains hypersensitivity to drug cues and drives reinstatement of seeking behaviors, as evidenced by increased dendritic spine density and reward sensitization. A 2024 review highlights the therapeutic potential of N-acetylcysteine (NAC), which, based on preclinical studies, attenuates ΔFosB accumulation in regions like the medial prefrontal cortex, restores glutamate homeostasis via the cystine-glutamate antiporter, and inhibits cue-induced reinstatement in cocaine and ethanol models, positioning NAC as a candidate for mitigating relapse.[65][66]

Associations with Diseases

Neurological Conditions

ΔFosB, the stable isoform of the FosB transcription factor, plays a significant role in the pathogenesis of levodopa-induced dyskinesias (LID), a common motor complication in Parkinson's disease patients undergoing long-term levodopa therapy. Overexpression of ΔFosB in the striatum has been shown to directly contribute to the abnormal involuntary movements characteristic of LID, as demonstrated in rodent models where viral-mediated striatal ΔFosB elevation replicated chronic levodopa's dyskinetic effects independently of dopamine levels. Repression of ΔFosB expression in the dorsal striatum ameliorates LID severity, highlighting its causal involvement in maladaptive striatal plasticity that underlies these side effects.[67] In the context of stress and aging, FosB exhibits age-dependent expression patterns in the hypothalamus, influencing neural responses to stressors. A 2022 study revealed that acute restraint stress induces sustained FOSB/ΔFOSB immunoreactivity in the paraventricular nucleus of the hypothalamus across different ages, indicating an age-independent response in this nucleus, though responses diminish with age in other brain regions.[68] Furthermore, fosB mutant mice display reduced resilience to chronic stress, as evidenced by heightened susceptibility to stress-induced behavioral deficits and failure to accumulate protective ΔFosB levels in key brain regions, underscoring FosB's role in bolstering hypothalamic stress tolerance mechanisms.[69] FosB is essential for electrophysiological adaptations following seizures, particularly in models of chronic electroconvulsive seizures. In fosB knockout mice, post-seizure molecular and cellular responses are disrupted, leading to attenuated behavioral seizure thresholds and impaired hippocampal electrophysiology, as originally reported in 1998 using fosB-/- models subjected to repeated electroconvulsive stimuli.[3] Recent confirmations in 2024 have extended these findings, showing that persistent ΔFosB activity modulates hippocampal excitability and limits recurrent seizure susceptibility through targeted gene regulation, reinforcing FosB's conserved role in seizure-induced neuroplasticity.[70] Within the hypothalamus, FosB maintains long-lasting expression in neuroendocrine neurons, contributing to physiological homeostasis. A 2025 investigation demonstrated sustained FosB/ΔFosB immunoreactivity in paraventricular and supraoptic nuclei following acute stress, persisting beyond transient FOS responses and localizing to corticotropin-releasing factor (CRF)- and vasopressin (AVP)-producing neurons, which supports adaptive neuroendocrine regulation for homeostasis and resilience.[71] This prolonged expression pattern positions FosB as a key mediator in hypothalamic circuits that sustain hormonal balance and stress recovery in neuroendocrine populations.

Oncogenic and Inflammatory Roles

FOSB plays a significant oncogenic role in various tumors through genetic rearrangements and transcriptional dysregulation. In osteoblastoma, a benign bone tumor, recurrent rearrangements involving FOSB, often fusing with promoters like WWTR1 or FOS itself, drive tumorigenesis by stabilizing the FOSB protein and enhancing its transcriptional activity, as identified in a 2018 study analyzing tumor genomes.[72] Similarly, ZFP36-FOSB fusions characterize a subset of epithelioid hemangiomas, particularly those with atypical features, leading to FOSB overexpression that promotes vascular proliferation and tumor formation.[73] In breast cancer models, FOSB, as part of the AP-1 transcription factor complex, contributes to invasive proliferation by modulating extracellular matrix remodeling, though direct targets like matrix metalloproteinase-9 (MMP-9) upregulation is more prominently linked to related AP-1 members such as Fra-1.[74] Recent research highlights FOSB's promotion of glioma cell proliferation and migration. High FOSB expression in glioma tissues correlates with increased cell viability and invasive potential, while its knockdown reduces proliferation and migration abilities, suggesting FOSB as a key regulator in glioma pathogenesis.[75] In the context of cancer immunotherapy, FOS-positive B cells, which express elevated levels of FOSB alongside FOS and JUNB, emerge as mediators of resistance across multiple tumor types, including melanoma and lung cancer, by fostering an immunosuppressive microenvironment that impairs T-cell responses.[76] In inflammatory pathologies, FOSB acts as a hub gene linking inflammatory bowel disease (IBD) to acute myocardial infarction (AMI). Bioinformatics analyses in 2025 identified FOSB, alongside THBD and PLAUR, as central nodes in shared pathways, where FOSB dysregulation exacerbates endothelial inflammation and thrombosis risk in comorbid IBD-AMI patients.[77] In IgA nephropathy, FOSB serves as a therapeutic target modulated by microRNA-27a-3p, which represses FOSB to attenuate podocyte and tubular cell proliferation, apoptosis resistance, and inflammatory cytokine release, thereby mitigating glomerular injury.[10] FOSB exhibits dual roles, functioning oncogenically in tumor contexts by activating proliferation genes but exerting protective effects in certain inflammatory settings through transcriptional repression of pro-inflammatory mediators, as evidenced in renal and vascular models where FOSB inhibition reduces pathology without promoting oncogenesis.

Research and Applications

Experimental Models

Knockout mouse models have been instrumental in elucidating the physiological roles of FosB. Constitutive fosB-null (fosB-/-) mice, generated by targeted disruption of the fosB gene, exhibit normal embryonic development and fertility but display impaired adult hippocampal neurogenesis, leading to spontaneous epileptic seizures and increased depressive-like behaviors.[78] These mice also show heightened vulnerability to psychostimulant effects, including enhanced locomotor sensitization to cocaine, which underscores FosB's role in modulating reward pathways and addiction susceptibility without altering initial drug responses.[19] Notably, fosB-/- mice maintain normal gross morphology and viability, highlighting FosB's non-essential role in basic development but critical function in adaptive neural responses.[79] Overexpression models, particularly of the stable ΔFosB isoform, provide causal insights into FosB's functions by simulating chronic stimulation states. Viral-mediated delivery of ΔFosB via adenoviral or herpes simplex virus vectors targeted to the nucleus accumbens (NAc) shell enhances reward sensitivity, increasing motivation for natural rewards like sucrose or sexual behavior and mimicking addiction-like phenotypes observed after repeated drug exposure.[80] For instance, intra-NAc ΔFosB overexpression elevates progressive ratio breakpoints in operant tasks, reflecting amplified incentive motivation.[81] Inducible transgenic systems, such as doxycycline-controlled bitransgenic mice expressing ΔFosB in dynorphin-positive striatal neurons, enable precise temporal and regional control, demonstrating sustained effects on behaviors like wheel-running and stress resilience upon induction.[82] In non-neuronal contexts, transgenic overexpression of ΔFosB in osteoblasts using the osteocalcin promoter induces osteosclerosis through enhanced bone formation and reduced adipogenesis via cell-autonomous mechanisms.[41] In vitro models complement in vivo studies by isolating cellular mechanisms. Mesenchymal stem cell (MSC) lines, such as human bone marrow-derived MSCs subjected to cyclic mechanical strain, upregulate FosB expression to drive osteogenic differentiation, as evidenced by increased alkaline phosphatase activity and mineralization markers.[83] This approach reveals FosB's role in mechanotransduction, where stretch-induced FosB promotes Runx2 activation and inhibits adipogenic pathways. Neuronal cultures, including primary hippocampal neurons transfected with ΔFosB, assess synaptic plasticity; overexpression reduces neuronal excitability and attenuates long-term potentiation (LTP) by modulating ion channel expression like Kv4.2, linking ΔFosB to activity-dependent circuit refinement.[84] Recent methodological advances have refined FosB studies at single-cell resolution. Single-cell RNA sequencing (scRNA-seq) applied to brain regions like the striatum in cocaine-exposed rodents maps ΔFosB isoform expression across cell types, revealing enrichment in D1-medium spiny neurons and correlation with transcriptional modules for plasticity and reward.[85] From 2020 onward, scRNA-seq datasets from human and mouse cortices have identified cell-type-specific FOSB expression changes in neurodegenerative diseases such as Alzheimer's and Parkinson's.[86] CRISPR-based editing further allows variant-specific manipulation; for example, CRISPR/Cas9 activation of endogenous FosB in cultured neurons or in vivo via AAV delivery induces ΔFosB without ectopic expression, dissecting its contributions to resilience circuits.[87] These tools, including guide RNAs targeting exon junctions for isoform knockout, facilitate precise interrogation of ΔFosB versus full-length FosB in addiction and epilepsy models.[56]

Therapeutic Targeting

Therapeutic targeting of FOSB, particularly its stable isoform ΔFosB, has emerged as a promising strategy in preclinical models for modulating maladaptive behaviors and pathological states associated with its overexpression. In addiction, histone deacetylase (HDAC) inhibitors have shown potential to counteract ΔFosB-mediated transcriptional repression by enhancing histone acetylation at target loci, thereby attenuating drug-seeking behaviors in rodent models of cocaine, morphine, and methamphetamine dependence.[88] Preclinical studies from around 2015 demonstrated that systemic or nucleus accumbens-targeted HDAC inhibition reduced ΔFosB levels and reinstated extinction of conditioned place preference, with ongoing research exploring class I HDAC-specific inhibitors for clinical translation. Similarly, N-acetylcysteine (NAC), a glutamate modulator and antioxidant, has been investigated for its ability to indirectly suppress ΔFosB-mediated relapse vulnerability; a 2024 preclinical analysis linked NAC's reduction in craving and drug-seeking to downstream modulation of ΔFosB targets in the mesolimbic pathway, supporting its evaluation in clinical trials for cocaine and opioid use disorders. In neurological conditions, antisense oligonucleotides (ASOs) targeting FOSB have been tested to mitigate levodopa-induced dyskinesias in Parkinson's disease models, where intrastriatal delivery reduced FOSB expression and abnormal involuntary movements in rats without altering therapeutic dopamine effects. Gene therapy approaches, including viral vector-mediated overexpression or knockdown of ΔFosB in hippocampal circuits, have demonstrated resilience-enhancing effects in chronic stress models, preventing depressive-like behaviors by restoring FOSB isoform balance in vulnerable brain regions. For oncogenic and inflammatory roles, microRNA-27a-3p (miR-27a-3p) mimics have been proposed to suppress FOSB expression in immunoglobulin A nephropathy, with in vitro studies showing that miR-27a-3p overexpression directly targets FOSB mRNA, inhibiting podocyte proliferation, apoptosis, and pro-inflammatory cytokine release in human kidney cells. In glioma, FOSB has been implicated as an oncogenic driver.[75] Despite these advances, therapeutic targeting of FOSB faces significant challenges, including achieving selectivity between full-length FOSB and its stable ΔFosB isoform to avoid disrupting normal transcriptional regulation, as well as overcoming the blood-brain barrier for central nervous system delivery using vectors or nanoparticles. As of 2025, no FOSB-modulating therapies have received regulatory approval, with most efforts confined to preclinical stages due to these hurdles and the need for long-term safety data.

References

  1. 2354 - Gene ResultFOSB FosB proto-oncogene, AP-1 transcription ...
  2. ΔFosB: A sustained molecular switch for addiction - PNAS
  3. Essential Role of the fosB Gene in Molecular, Cellular, and ...
  4. Protein FosB - P53539 - UniProt
  5. fosB is a transforming gene encoding a transcriptional activator
  6. Transcription Factor FosB - an overview | ScienceDirect Topics
  7. Fosb MGI Mouse Gene Detail - FBJ osteosarcoma oncogene B
  8. Structure and mapping of the fosB gene. FosB downregulates the ...
  9. Structure and mapping of the fos B gene. FosB downregulates the ...
  10. MicroRNA-27a-3p directly targets FosB to regulate cell proliferation ...
  11. FOSB Gene - GeneCards | FOSB Protein | FOSB Antibody
  12. Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin ...
  13. Both products of the fosB gene, FosB and its short form, FosB/SF ...
  14. identification of FosB degron domains and implications for ... - PubMed
  15. Proteasome‐dependent and ‐independent mechanisms for FosB ...
  16. Regulation of fosB and DeltafosB mRNA expression - PubMed - NIH
  17. Wavelength-specific Induction of Immediate Early Genes by ...
  18. ΔFosB: a transcriptional regulator of stress and antidepressant ...
  19. ΔFosB: A sustained molecular switch for addiction - PMC - NIH
  20. The product of a novel growth factor activated gene, fos B, interacts ...
  21. Transcription Factor FosB - an overview | ScienceDirect Topics
  22. Cyclic strain induces FosB and initiates osteogenic differentiation of ...
  23. Late expression of FosB transcription factor in 4-aminopyridine ...
  24. Regulation of ΔFosB Stability by Phosphorylation - PMC
  25. Transcriptional activation and transformation by FosB protein require ...
  26. Fos family members induce cell cycle entry by activating cyclin D1
  27. Adipogenesis - PMC - PubMed Central
  28. The jun and fos protein families are both required for cell cycle ... - NIH
  29. Antagonistic Regulation of Cell-Matrix Adhesion by FosB and ΔFosB ...
  30. Stable Variants of ΔFosB Induced in Brain by Chronic Treatments
  31. Regulation of gene expression in osteoblasts - IUBMB Journal - Wiley
  32. Doubly Truncated FosB Isoform (Δ2ΔFosB) Induces Osteosclerosis ...
  33. ΔFosB is part of a homeostatic mechanism that protects the epileptic ...
  34. Regulation of fosB and ΔfosB mRNA Expression: In Vivo and In Vitro ...
  35. Activation of the Transcription Factor FosB/Activating Protein-1 (AP-1 ...
  36. New roles for AP-1/JUNB in cell cycle control and tumorigenic cell ...
  37. Fos Family Members Induce Cell Cycle Entry by Activating Cyclin D1
  38. JunB contributes to Id2 repression and the epithelial–mesenchymal ...
  39. The potential of activator protein 1 (AP-1) in cancer targeted therapy
  40. Mechanism of NF-κB-Dependent Regulation of AP-1 Activity - PMC
  41. ΔFOSB: A Potentially Druggable Master Orchestrator of Activity ...
  42. ΔFosB Induces Osteosclerosis and Decreases Adipogenesis by Two ...
  43. cAMP/PKA pathway activation in human mesenchymal stem cells in ...
  44. Experience-Dependent Induction of Hippocampal ΔFosB Controls ...
  45. https://doi.org/10.1523/JNEUROSCI.2083-15.2015
  46. Neuroplastic changes in c‐Fos, ΔFosB, BDNF, trkB, and Arc ...
  47. ΔFosB Decreases Excitability of Dorsal Hippocampal CA1 Neurons
  48. ΔFosB-mediated alterations in dopamine signaling are normalized ...
  49. Differential induction of FosB isoforms throughout the brain by ...
  50. Manipulating ΔFOSB in D1-type Medium Spiny Neurons of the ...
  51. (PDF) The Influence of Delta FosB in the Nucleus Accumbens on ...
  52. ΔFosB Regulates Wheel Running - PMC - PubMed Central
  53. DeltaFosB in the nucleus accumbens is critical for reinforcing effects ...
  54. FosB differentially modulates nucleus accumbens direct and indirect ...
  55. Circuit-specific hippocampal ΔFosB underlies resilience to stress ...
  56. Transcriptional mechanisms of addiction: role of ΔFosB - PMC
  57. ΔFosB Mediates Epigenetic Desensitization of the c-fos Gene After ...
  58. Overexpression of DeltaFosB in nucleus accumbens mimics the ...
  59. Cell-type-specific whole-genome landscape of ΔFOSB binding in ...
  60. https://doi.org/10.1073/pnas.1221742110
  61. https://doi.org/10.1073/pnas.191352698
  62. https://doi.org/10.1523/JNEUROSCI.1531-08.2008
  63. Role of striatal ΔFosB in l-Dopa–induced dyskinesias of ... - PNAS
  64. Age-Dependent FOSB/ΔFOSB Response to Acute and Chronic ...
  65. FosB is essential for the enhancement of stress tolerance, and ...
  66. Persistent ∆FosB expression limits recurrent seizure activity and ...
  67. Long-lasting expression of FosB/ΔFosB immunoreactivity following ...
  68. fosB-Null Mice Display Impaired Adult Hippocampal Neurogenesis ...
  69. normal development of FosB knockout mice - PubMed
  70. ΔFosB in the Nucleus Accumbens Regulates Food-Reinforced ...
  71. The Influence of ΔFosB in the Nucleus Accumbens on Natural ... - NIH
  72. ΔFosB Regulates Wheel Running - Journal of Neuroscience
  73. Cyclic strain induces FosB and initiates osteogenic differentiation of ...
  74. ΔFosB Decreases Excitability of Dorsal Hippocampal CA1 Neurons
  75. Single-nucleus genomics in outbred rats with divergent cocaine ...
  76. Single-Cell Cortical Transcriptomics Reveals Common and Distinct ...
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC8501456
User Avatar
No comments yet.